Business
InvestmentPitch Media Video Discusses Resverlogix and Report of its Apabetalone Drug Meeting Primary Endpoint in Pulmonary Arterial Hypertension Investigator Led Pilot Study - Video Available on Investmentpitch.com
Vancouver, British Columbia--(Newsfile Corp. - September 9, 2021) - Resverlogix Corp. (TSX: RV...
About this update from Resverlogix Corp.
[{"type":"text","content":"InvestmentPitch Media Video Discusses Resverlogix and Report of its Apabetalone Drug Meeting Primary Endpoint in Pulmonary Arterial Hypertension Investigator Led Pilot Study - Video Available on Investmentpitch.comVancouver, British Columbia--(Newsfile Corp. - September 9, 2021) - Resverlogix Corp. (TSX: RVX) (OTC Pink: RVXCF) reported that its Apabetalone drug met its primary endpoint in a pulmonary arterial hypertension or 'PAH' investigator led pilot study. Resverlogix, a world leader in epigenetics, or gene regulation, has been pioneering a technology which has the ability to turn multiple disease genes on or off, without changing the human DNA.InvestmentPitch.com has produced a \"video\" which discusses this news. If this link is not enabled, please visit www.InvestmentPitch.com and enter \"Resverlogix\" in the search box. Cannot view this video? Visit:http://www.investmentpitch.com/video/1_0wgj9gb7/Resverlogix-reported-that-its-Apabetalone-drug-met-its-primary-endpoint-in-a-pulmonary-arterial-hypertension-or-PAH-investigator-led-pilot-studyWhile most of us know that we inherit our genes via DNA, few of us realize the activity of these genes is determined by epigenetics, which literally means \"on top of\" genetics. Epigenetics has become an exciting forefront for the discovery of new medicines, such as Apabetalone, an advanced cardiovascular drug being developed by Resverlogix.In February 2020, Apabetalone became the first therapy of its kind to have been granted US FDA Breakthrough Therapy Designation, for a major cardiovascular indication, to help facilitate a time-efficient drug development program including planned clinical trials and plans for expediting the manufacturing development strategy.Apabetalone is a first-in-class, small molecule that is a selective bromodomain and extra-terminal, or BET, inhibitor, an epigenetic mechanism that can regulate disease-causing genes. Apabetalone selectively targets the second bromodomain or 'BD2' within the BET proteins, producing a specific set of biological effects with potentially important benefits for patients with COVID-19, high-risk cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease treated with hemodialysis, neurodegenerative disease, Fabry disease, peripheral artery disease and other orphan diseases, while maintaining a well descr...